Physician profile
Brandon Yim
NPI 1639599616
$6,582.20
in general payments reported to CMS, 2019-2025
19 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.51 · 2020: $82.72 · 2021: $474 · 2022: $1,111 · 2023: $1,264 · 2024: $1,686 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,798 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,797.83 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,281.84 | 2020-2025 | Rinvoq, Skyrizi, Creon |
| Janssen Biotech, INC. | $772.48 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $479.55 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $262.80 | 2023-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $214.31 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $208.25 | 2021-2025 | Entyvio |
| Pfizer INC. | $200.72 | 2021-2025 | |
| Celgene Corporation | $196.96 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $170.81 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $157.05 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $136.27 | 2019-2024 | |
| Regeneron Pharmaceuticals, INC. | $128.70 | 2023 | Dupixent |
| Endogastric Solutions, INC | $95.15 | 2024 | Esophyx |
| Medtronic, INC. | $91.53 | 2025 | Manoscan |
| Celltrion USA INC. | $60.03 | 2025 | Vegzelma |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $55.03 | 2025 | Iqirvo |
| Lilly USA, LLC | $33.40 | 2024 | Omvoh |
| Mallinckrodt Hospital Products INC. | $24.16 | 2024 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Yim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.